AHA 2026 | Sungen Biomed’s First-in-Class Anti-KCNQ1 Monoclonal Antibody SGC007 Debuts with the Preclinical Data

Source: Hotgen Biotech
Date: 2026-11-16
Back to List

Recently, Sungen Biomed, a subsidiary of Hotgen Biotech, for the first time publicly disclosed the preclinical data of SGC007, the world’s first KCNQ1-targeting monoclonal antibody, at the American Heart Association (AHA) Scientific Sessions, opening a new antibody-based therapeutic approach for the precision treatment of congenital and acquired long QT syndrome (LQTS).

62340795_1794796326.jpg
On local time November 8, Dr. Chang Cui, from the Department of Cardiovascular Medicine at Nanjing Medical University, presented a poster on behalf of the research team and all collaborators in Basic Science Zone 2, titled “Development of a First-in-Class KCNQ1-Targeting Monoclonal Antibody for Precision Therapy of Long QT Syndrome” (poster number MDP1502). Unlike the sessions which focused on clinical data, Basic Science Zone addressed research at the mechanistic and molecular level.

Long QT syndrome (LQTS) is a life-threatening cardiac ion-channel disorder and falls into two broad categories: congenital forms caused by inherited mutations, and acquired forms triggered by drugs and other factors. Affected patients show abnormal myocardial repolarization and a prolonged QT interval, which can readily cause syncope and malignant arrhythmias and, in severe cases, sudden cardiac death, with particularly high risk among adolescents. Current clinical management relies mainly on beta-blockers and implantable devices, and no specific therapy is available that can directly restore ion-channel function, leaving a substantial unmet clinical need.

SGC007 was jointly developed by Nanjing Medical University and Sungen Biomed, and is the world’s first monoclonal antibody modulating the opening of the KCNQ1 potassium channel. By specifically binding to KCNQ1 channels, it enhances the cardiac repolarizing current IKs, increases myocardial repolarization reserve and shortens the abnormally prolonged action potential duration, thereby suppressing malignant ventricular arrhythmias — establishing a completely new mechanism of action for monoclonal antibody therapy of arrhythmias.

Preclinical studies showed that, at the cellular level, SGC007 significantly shortened the action potential duration (APD) of iPSC-CMs carrying LQT1/LQT2 mutations as well as drug-induced iPSC-CMs for acquired LQTS, while having no effect on healthy cardiomyocytes, demonstrating good specificity. In guinea pig models of LQTS, SGC007 dose-dependently shortened the QTc interval and the ventricular effective refractory period, and significantly suppressed the occurrence of ventricular tachycardia.

In terms of drug developability, SGC007 showed cross-species binding, achieved desirable drug exposure after subcutaneous administration, and had a long half-life following Fc engineering, supporting convenient, low-frequency subcutaneous dosing and helping with patient adherence. In toxicity studies, no drug-related toxicity was observed, indicating a favorable safety window.

This AHA presentation marked the unveiling of SGC007 research to the international academic community. Leveraging Nanjing Medical University’s deep foundation in basic cardiovascular research and Sungen Biomed’s capabilities in first-in-class antibody development and translational medicine platforms, the two parties are advancing industry–academia–research collaboration to translate innovative therapies for inherited arrhythmias into clinical application.

share